Press Release
MetaCen Therapeutics Demonstrates Efficacy in Reducing Advanced Glycation End Products (AGEs)
2024.12.10 09:27- 작성자 관리자
- 조회 77
KF140 Probiotic Secures International Patents
MetaCen Therapeutics (CEO Myoung-Gyu Park) announced that its KF140 probiotic, developed to reduce Advanced Glycation End Products (AGEs), has successfully obtained patents in South Korea, the United States, Australia, Canada, India, and Japan.
The company also reported that patent registration processes are underway in Brazil, China, Europe, Indonesia, and Vietnam, paving the way for a significant leap forward in the global healthcare market.
KF140 has demonstrated exceptional efficacy in inhibiting or removing AGEs. Related research findings were published in June 2022 in the SCI-indexed international journal "Frontiers in Nutrition".
Additionally, researchers from Seoul National University Bundang Hospital and Yonsei University Severance Hospital in Yongin participated in studies that demonstrated the significant efficacy of the composite material ‘MCT192’, which includes the AGE-degrading probiotic KF140. Clinical trials involving patients with fatty liver, hepatitis, liver fibrosis, glycated hemoglobin, and diabetes showed meaningful results.
AGEs (Advanced Glycation End Products) are recognized as a major contributor to various chronic diseases, including diabetes, aging, liver disease, and cardiovascular disorders. Developing technologies to reduce AGEs is a globally significant area of research.
A representative from MetaCen Therapeutics stated, “The multinational patent registrations for KF140 probiotic affirm the scientific excellence of our AGE-reduction technology on a global scale. Building on this achievement, we will continue to develop healthcare products and solidify our presence in the global market.”
Reporter: Yi Seul Kim, yi_seul0717@kpanews.co.kr
Source: [Korea Pharmaceutical Association] (https://www..kpanews.co.kr)
MetaCen Therapeutics (CEO Myoung-Gyu Park) announced that its KF140 probiotic, developed to reduce Advanced Glycation End Products (AGEs), has successfully obtained patents in South Korea, the United States, Australia, Canada, India, and Japan.
The company also reported that patent registration processes are underway in Brazil, China, Europe, Indonesia, and Vietnam, paving the way for a significant leap forward in the global healthcare market.
KF140 has demonstrated exceptional efficacy in inhibiting or removing AGEs. Related research findings were published in June 2022 in the SCI-indexed international journal "Frontiers in Nutrition".
Additionally, researchers from Seoul National University Bundang Hospital and Yonsei University Severance Hospital in Yongin participated in studies that demonstrated the significant efficacy of the composite material ‘MCT192’, which includes the AGE-degrading probiotic KF140. Clinical trials involving patients with fatty liver, hepatitis, liver fibrosis, glycated hemoglobin, and diabetes showed meaningful results.
AGEs (Advanced Glycation End Products) are recognized as a major contributor to various chronic diseases, including diabetes, aging, liver disease, and cardiovascular disorders. Developing technologies to reduce AGEs is a globally significant area of research.
A representative from MetaCen Therapeutics stated, “The multinational patent registrations for KF140 probiotic affirm the scientific excellence of our AGE-reduction technology on a global scale. Building on this achievement, we will continue to develop healthcare products and solidify our presence in the global market.”
Reporter: Yi Seul Kim, yi_seul0717@kpanews.co.kr
Source: [Korea Pharmaceutical Association] (https://www..kpanews.co.kr)